Post-COVID-19 patients revealed higher levels of PR3-ANCA, IgM, and IgG2 compared to patients with ASCVD (p = 0.016; p = 0.011; p = 0.036, respectively), but not to healthy controls. This evidence concerns the gene CD40LG and COVID-19.